About | Free Trial

Last Update

2016-05-21T00:00:00.000Z

This profile was last updated on . .

Is this you? Claim your profile.

Wrong Curt Bilby?

Dr. Curt Bilby

President and Chief Executive Officer

Terapio Corporation

Direct Phone: (512) ***-****       

Email: c***@***.com

Terapio Corporation

401 Congress Suite 2950

Austin, Texas 78701

United States

Company Description

Terapio is a biopharmaceutical company specializing in the development of a pipeline of therapies based on the transport protein, RLIP76. Terapio is based in Austin, Texas and funded by Santé Ventures. more

Find other employees at this company (7)

Background Information

Employment History

Managing Director and Chief Executive Officer

Stealth Art

President and Chief Executive Officer

Seahawk Biosystems Corporation

Affiliations

Board Member
Austin Technology Council

Board Member
Savara Pharmaceuticals

Education

PhD

engineering degrees

Auburn University

engineering degrees

Rose-Hulman Institute of Technology

honorary doctorate

Rose-Hulman

Web References (125 Total References)


Curt Bilby, PhD ...

www.cprit2012.org [cached]

Curt Bilby, PhD (Moderator)

CPRIT 2012 Conference
...
Curt Bilby, PhD (Moderator) President and Chief Executive Officer, Terapio
Dr. Bilby has been the President and CEO of Terapio since 2007 and has over twenty years of executive leadership experience in the biotechnology, healthcare and information technology sectors both domestically and in Europe. Previously, Dr. Bilby was President and CEO of Seahawk Biosystems Corporation which developed a biosensor based magnetic biochip technology developed at the Naval Research Laboratory. Prior to that, he was the Chairman and CEO of Evacyte Corporation, a company developing laser-based cancer detection and cell diagnostics using the internationally recognized Optical Cell Stretcher technology developed at The University of Texas at Austin. Dr. Bilby also served as the Président-Directeur Général of the multi-national healthcare company Eurimed, S.A. headquartered in Paris, France. Dr. Bilby has engineering degrees from Rose-Hulman Institute of Technology and Auburn University and conducted his doctoral work at The University of Texas at Austin. Of note is his selection as a Distinguished Young Alumnus of Rose-Hulman where he was also awarded an honorary doctorate.


Tag Archive for ‘XCOR’ at Parabolic Arc

www.parabolicarc.com [cached]

1. Monday, Feb. 17, 2014, 2-3:30 PM PST (5-6:30 PM EST, 4-5:30 PM CST): We welcome back DR. CURT BILBY CEO of Terapio with updates on RLIP 76 for radiation exposure.


Dr. Curt ...

archived.thespaceshow.com [cached]

Dr. Curt Bilby

...
Dr. Curt Bilby
Dr. Curt Bilby, the President and CEO of Terapio since 2007, has over twenty years of executive leadership experience in the biotechnology, healthcare and information technology sectors both domestically and in Europe. Previously, Dr. Bilby was President and CEO of Seahawk Biosystems Corporation which developed a biosensor based on technology developed at the Naval Research Laboratory. Prior to that, he was the Chairman and CEO of Evacyte Corporation, a company developing laser-based cancer detection and cell diagnostics using technology developed at The University of Texas at Austin. Dr. Bilby also served as the Président-Directeur Général of the multi-national company Eurimed, S.A. headquartered in Paris, France. Dr. Bilby has engineering degrees from Rose-Hulman Institute of Technology and Auburn University and conducted his doctoral work at The University of Texas at Austin. Of note is his selection as a Distinguished Young Alumnus of Rose-Hulman where he was also awarded an honorary doctorate.
Appeared on the following broadcasts: #2189 - Guest: Dr. Curt Bilby. Topics: Update on developing RLIP 76 as a radiation... (2/17/2014) #1878 - Guests: Dr. Curt Bilby, Dr. Elizabeth Leffel.


Guest: Dr. Curt ...

archived.thespaceshow.com [cached]

Guest: Dr. Curt Bilby

Guest: Dr. Curt Bilby. Topics: Update on developing RLIP 76 as a radiation countermeasure drug as we as for possible use in space.
...
We welcomed back Dr. Curt Bilby, CEO of Terapio ( http://terapio.com), to update us on progress with the radiation countermeasure drug RLIP 76, including its potential use to combat and reduce space radiation risks. We had a one hour update with Dr. Bilby which started with the basics of RLIP 76 which is a naturally occurring protein in the human body. Dr. Bilby went through the basics with us, told us that since he was last on the show, they have stabilized the shelf life of the product by being able to store it as a white powder and then when needed mix it with saline. He described the pathway in the body by which RLIP 76 works which is really a supplement to what the body already produces. We talked about their experimentation and testing under what is known as the FDA Animal Rule which he explained in detail to us. He also talked about toxicology studies as well as the type of radiation used in testing the product by the independent testing labs at the University of Indiana and Maryland under the management of the NIH.
...
Near the end of our discussion, Dr. Bilby went through the four phases of testing with us as required by the FDA. We also talked extensively about the FDA Emergency Use Authorization for any drug and a listener wanted to know if a Mars mission could apply & be approved for using RLIP 76 as part of their life support mission planning. Just as the show ended, Doug sent in an email asking about the probability of NASA increasing the amount of radiation allowed if the crews used RLIP 76. Dr. Bilby answered him by saying pharmaceuticals might change the profile & exposure levels as current standards are for unmedicated crews. But it was far from certain & NASA might not be the determining agency on the matter. Post your comments/questions on TSS Blog. You can contact Dr. Bilby through me or his website.
About our guest...
Dr. Curt Bilby Dr. Curt Bilby, the President and CEO of Terapio since 2007, has over twenty years of executive leadership experience in the biotechnology, healthcare and information technology sectors both domestically and in Europe. Previously, Dr. Bilby was President and CEO of Seahawk Biosystems Corporation which developed a biosensor based on technology developed at the Naval Research Laboratory. Prior to that, he was the Chairman and CEO of Evacyte Corporation, a company developing laser-based cancer detection and cell diagnostics using technology developed at The University of Texas at Austin. Dr. Bilby also served as the Président-Directeur Général of the multi-national company Eurimed, S.A. headquartered in Paris, France. Dr. Bilby has engineering degrees from Rose-Hulman Institute of Technology and Auburn University and conducted his doctoral work at The University of Texas at Austin. Of note is his selection as a Distinguished Young Alumnus of Rose-Hulman where he was also awarded an honorary doctorate.


Space Show Website Newsletter

www.businessinspace.com [cached]

Monday, Feb. 17: Dr. Curt Bilby of Terapio

Similar Profiles

Other People with this Name

Other people with the name Bilby

Lisa Bilby
Royal School of Needlework

David Bilby
CONNS INC

John Bilby
Stoll Keenon Ogden PLLC

Naomi Bilby
Quantum Windows Limited

Monty Bilby
Tarrant County

Browse ZoomInfo's Business Contact Directory by City

Browse ZoomInfo's
Business People Directory

Browse ZoomInfo's
Advanced Company Directory